We found that ILT2+NKp46−CD56dim NK cells had impaired cytolytic and antibody-dependent cellular cytotoxicity (ADCC) capacities in HCC patients, and that these capacities were restored by anti-ILT2 antibody treatment. This evidence concerns the gene LILRB1 and hepatocellular carcinoma.